- Home
- ESP vs AGEN Comparison
ESP vs AGEN Comparison
Compare ESP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESP
- AGEN
- Stock Information
- Founded
- ESP 1928
- AGEN 1994
- Country
- ESP United States
- AGEN United States
- Employees
- ESP N/A
- AGEN N/A
- Industry
- ESP Industrial Machinery/Components
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESP Technology
- AGEN Health Care
- Exchange
- ESP Nasdaq
- AGEN Nasdaq
- Market Cap
- ESP 84.1M
- AGEN 96.2M
- IPO Year
- ESP N/A
- AGEN 2000
- Fundamental
- Price
- ESP $27.92
- AGEN $3.32
- Analyst Decision
- ESP
- AGEN Buy
- Analyst Count
- ESP 0
- AGEN 3
- Target Price
- ESP N/A
- AGEN $10.50
- AVG Volume (30 Days)
- ESP 13.7K
- AGEN 360.9K
- Earning Date
- ESP 02-12-2025
- AGEN 03-13-2025
- Dividend Yield
- ESP 3.11%
- AGEN N/A
- EPS Growth
- ESP 31.14
- AGEN N/A
- EPS
- ESP 2.45
- AGEN N/A
- Revenue
- ESP $43,917,522.00
- AGEN $160,427,000.00
- Revenue This Year
- ESP N/A
- AGEN N/A
- Revenue Next Year
- ESP N/A
- AGEN $26.02
- P/E Ratio
- ESP $11.48
- AGEN N/A
- Revenue Growth
- ESP 18.62
- AGEN 59.00
- 52 Week Low
- ESP $20.20
- AGEN $2.50
- 52 Week High
- ESP $33.00
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- ESP 51.06
- AGEN 45.96
- Support Level
- ESP $25.40
- AGEN $3.09
- Resistance Level
- ESP $28.64
- AGEN $3.68
- Average True Range (ATR)
- ESP 0.99
- AGEN 0.25
- MACD
- ESP 0.07
- AGEN -0.03
- Stochastic Oscillator
- ESP 73.72
- AGEN 23.00
About ESP Espey Mfg. & Electronics Corp.
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).